FDA Grants Durvalumab Breakthrough Designation for NSCLC

July 31, 2017 – The FDA has granted durvalumab a breakthrough therapy designation to treat patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation. AstraZeneca and its global biologics research and development arm MedImmune, announced the FDA action in a press release. The designation, which will expedite the development and review of durvalumab … (leggi tutto)